The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?
Featured:
André BaruchelDuring the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to André Baruchel, Hôpital Robert-Debré, Paris, FR. We asked, What is new in chimeric antigen receptor (CAR) T-cell therapy for pediatric acute lymphoblastic leukemia.
What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?
Baruchel discusses long-term results of clinical trials investigating CAR T-cell therapy and the benefits for pediatric patients with advanced acute lymphoblastic leukemia. He also mentions potential causes for relapse after CAR T-cell treatment and how new constructs could tackle this problem.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?